Clinical Trial Update: A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens [Phase 2]

View source ↗

Summary

Phase 2 study evaluating subcutaneous daratumumab in combination with standard multiple myeloma regimens; results were posted after completion in January 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DARZALEX (daratumumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2022-01-12